| 发明名称 |
Solid compositions |
| 摘要 |
The present invention features solid compositions comprising a selected HCV inhibitor in an amorphous form. In one embodiment, the selected HCV inhibitor is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant. |
| 申请公布号 |
US9034832(B2) |
申请公布日期 |
2015.05.19 |
| 申请号 |
US201414507267 |
申请日期 |
2014.10.06 |
| 申请人 |
AbbVie Inc. |
发明人 |
Gao Yi;Zhang Geoff |
| 分类号 |
A61K31/4184;A61K38/06;A61K47/32;A61K9/10;A61K38/05;A61K38/07;A61K45/06;A61K9/14;A61K9/16;A61K31/403;A61K31/4178;A61K31/439;A61K31/4709;A61K31/497;A61K31/501;A61K31/519;A61K31/549;A61K31/55;A61K31/7068;A61K31/708 |
主分类号 |
A61K31/4184 |
| 代理机构 |
|
代理人 |
Zhang Xu |
| 主权项 |
1. A solid oral dosage form comprising a solid solution which includes: copovidone, and optionally a pharmaceutically acceptable surfactant. |
| 地址 |
North Chicago IL US |
